abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

이 페이지는 한국어로 제공되지 않으며 English로 표시됩니다.

기사

2007년 8월 6일

저자:
S. Murari, Reuters

Chennai court rejects Novartis patent challenge [India]

A court rejected on Monday a challenge by Novartis to Indian law that denies patents for minor improvements to known drugs, and the Swiss drug giant said it was unlikely to appeal...The court in Chennai rejected the challenge, saying it had no jurisdiction on whether Indian patent laws complied with intellectual property rules set by the World Trade Organisation, as Novartis had questioned. "We disagree with this ruling, however we likely will not appeal to the Supreme Court," a Novartis spokeswoman said by phone from Basel, in Switzerland. "We await the full decision to better understand the court's position."...Novartis says the Indian patent system stifles innovation. Critics of Novartis say changes to the law would affect the supply of affordable anti-AIDS drugs from India, one of the biggest makers of generic drugs.

타임라인